Back to News
Market Impact: 0.32
Pfizer Secures Expanded FDA Label For Talzenna-Xtandi In HRR-Mutated Metastatic Prostate Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA expanded approval of Pfizer's TALZENNA in combination with XTANDI to treat men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. The article text is truncated after mentioning homologous, so no further eligibility details or commercial implications are available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
PFE0.65
More News
- Anthropic IPO Seeks Investors, With Risks of Catastrophe, Rogue AI
- Analysis-Hold or sell? High Treasury yields spur US banks to rethink bond portfolios
- Indian investors rush to Nvidia, SpaceX, Apple as local trading apps roll out access to U.S. stocks
- Stifel’s surprise gaming pick leads a sector bracing for a choppy earnings season
- The Trump admin said energy costs were a small price to pay in Iran war, but U.S. consumers are paying nearly 8x more than anyone else in fuel costs
- Artiva halts AlloNK development, cuts 94% of workforce